Submit Manuscript  

Article Details


MicroRNAs implications in the onset, diagnosis, and prognosis of osteosarcoma

Author(s):

Negin Ebrahimi, Saeed Aslani, Farhad Babaie, Maryam Hemmatzadeh, Zahra Pourmoghadam, Gholamreza Azizi, Farhad Jadidi-Niaragh and Hamed Mohammadi*   Pages 1 - 17 ( 17 )

Abstract:


Osteosarcoma (OS) is a primary bone malignancy, which has high incidence in children and adolescents. The affected cells and tissues show the properties of drug-resistance and the prognosis remains poor in OS, therefore there is an essential need for novel therapeutic approaches. MicroRNAs (miRNAs) expression pattern has been established to be involved in the pathogenesis of OS. miRNAs are small non-coding RNA molecules, which negatively regulate gene expression at post-transcriptional level. There are copious miRNAs that have a critical role in the onset of the disease, modulation of disease progression, and response to treatment. At the moment, the recently launched version 3.0 of Human MicroRNA Disease Database (HMDD v3.0) reports that 194 miRNAs are dysregulated in OS that might be involved in proliferation, migration, invasion, and epithelial-mesenchymal transition of tumor cells. The balance between oncogene and tumor suppressor miRNAs has vital importance in the final fate of the cell behaviors in OS. Additionally, networks of miRNAs may act in concert to induce oncogenic or tumor-suppressing properties during the initiation or progression of OS. Up or downregulation of these miRNAs affect the status of the disease, during or after therapy. To date, over 40 miRNAs have been identified in OS disease that possess oncogenic or tumor-suppressing properties, and treatment approaches are trying to establish a proper level of such miRNAs in favor of OS therapy. The role of miRNAs involved in the pathogenesis of OS and their therapeutic potential are the reference points in this review article.

Keywords:

Osteosarcoma; MicroRNA; Metastasis; Angiogenesis; Target-therapy; Autophagy.

Affiliation:

Department of International Medicine, Faculty of Medicine, Health sciences University, Istanbul,, Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran,, Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz,, Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz,, Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz,, Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj,, Immunology Research Center, Tabriz University of Medical Sciences, Tabriz,, Department of Immunology, School of Medicine, Alborz University of Medical Sciences, Karaj



Read Full-Text article